The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
复制标题
DOI：
10.1016/j.jaad.2020.05.007
复制
发表时间：
2020-11
影响因子：
13.8
通讯作者：
Krueger JG
中科院分区：
文献类型：
--
作者：
Frew JW;Navrazhina K;Grand D;Sullivan-Whalen M;Gilleaudeau P;Garcet S;Ungar J;Krueger JG
化脓性汗腺炎是一种角化的自身炎症性疾病，伴有T辅助型17细胞因子的失调。Brodalumab是一种针对白细胞介素（IL） 17受体a受体的单克隆抗体。评估布罗达鲁单抗在中重度HS患者第12周和第24周的安全性、耐受性和临床反应。10名无炎症性肠病史的参与者在第0、1和2周皮下注射brodalumab 210 mg/1.5 mL，此后每2周注射一次，直到第24周。评估参与者的不良事件（2/3级不良事件）和临床反应（化脓性汗腺炎临床反应[HiSCR]， Sartorius，国际化脓性汗腺炎严重程度评分系统[IHS4]），包括超声检查和皮肤活检。所有10名参与者都完成了这项研究。未报告与使用brodalumab相关的2/3级不良事件。所有患者（100%）在第12周达到HiSCR， 80%达到IHS4分类改变。HiSCR的实现最早发生在第2周，可能是由于brodalumab对IL-17A、IL-17C和IL-17F的独特阻断。在疼痛、瘙痒、生活质量和抑郁方面都有显著改善。在这个HS队列中，Brodalumab耐受性良好，没有严重的不良事件和临床结果的改善。晚期患者可能需要改变剂量频率，这需要进一步探讨。
Hidradenitis suppurativa is an autoinflammatory disorder of keratinization, with dysregulation of T helper type 17 cytokines. Brodalumab is a monoclonal antibody that targets the interleukin (IL) 17 receptor A receptor. To assess the safety and tolerability and clinical response at weeks 12 and 24 of brodalumab in moderate to severe HS. Ten participants with no history of inflammatory bowel disease were administered brodalumab 210 mg/1.5 mL subcutaneously at weeks 0, 1, and 2 and every 2 weeks thereafter until week 24. Participants were assessed for adverse events (grade 2/3 adverse events) and clinical response (Hidradenitis Suppurativa Clinical Response [HiSCR], Sartorius, International Hidradenitis Suppurativa Severity Scoring System [IHS4]), including ultrasonography and skin biopsies. All 10 participants completed the study. No grade 2/3 adverse events associated with the use of brodalumab were reported. All patients (100%) achieved HiSCR, and 80% achieved IHS4 category change at week 12. HiSCR achievement occurred as early as week 2, likely due to the unique blockade of IL-17A, IL-17C, and IL-17F by brodalumab. Significant improvements were seen in pain, itch, quality of life, and depression. Brodalumab was well tolerated in this HS cohort, with no serious adverse events and improvement in clinical outcomes. Alterations in dose frequency may be required in those with advanced disease, which requires further exploration.
登录
查看更多内容
影响因子：
6.5
作者：
Witte-Haendel, Ellen;Wolk, Kerstin;Sabat, Robert
通讯作者：
Sabat, Robert
影响因子：
10.3
作者：
Nielsen, R. M.;Andersen, P. Lindso;Jemec, G. B.
通讯作者：
Jemec, G. B.
影响因子：
10.9
作者：
Tzanetakou, Vassiliki;Kanni, Theodora;Giamarellos-Bourboulis, Evangelos J.
通讯作者：
Giamarellos-Bourboulis, Evangelos J.
影响因子：
4.4
作者：
Russell, Chris B.;Rand, Hugh;Martin, David A.
通讯作者：
Martin, David A.
影响因子：
--
作者：
BECK, AT;ERBAUGH, J;MENDELSOHN, M
通讯作者：
MENDELSOHN, M